A1: Develop a Case Study and Secondary Research

Agile project Management

**Project Lightning Speed: The Pfizer–BioNTech COVID-19 Vaccine** *Comirnaty* **Development and Deployment**

During the COVID-19 pandemic, when every moment mattered, there was immense pressure to develop a vaccine for the newly discovered coronavirus. Just two days after the World Health Organization (WHO) declared the pandemic on March 11, 2020, Pfizer, a leading American pharmaceutical company, partnered with the German biotech firm BioNTech to co-develop an mRNA-based vaccine. The project was named *Project Lightning Speed* in response to the urgent need, as millions of lives were being lost daily.

The project successfully delivered the vaccine for human use within just nine months of the pandemic's declaration. This rapid progress was driven in part by the foresight of BioNTech's CEO, an immunologist, who had already started researching the coronavirus when news of its emergence in Wuhan, China, first broke. By March 13, he had established a partnership with Pfizer to accelerate the development of a vaccine. (Lovelace Jr., 2021)

The timeline of the projects progress can be seen below:

A blue and yellow table with black text

AI-generated content may be incorrect.

Challenges encountered:

* **Accelerated Timeline**: While traditional vaccine development typically takes 10–15 years, Project Lightspeed achieved the development of the COVID-19 vaccine *Comirnaty* within just 9 months. The primary challenge was scaling up manufacturing rapidly to ensure a continuous global supply for unprecedented population size. (Pfizer, 2021)
* **Regulatory Navigation**: The project adopted an agile regulatory strategy involving rolling submissions and real-time data sharing with agencies, which enabled emergency use authorization by December 2020.
* **Stakeholder Complexity**: The project involved a wide array of global stakeholders-including Pfizer, BioNTech, regulatory bodies (e.g., FDA, EMA), international governments, healthcare systems, and the global public,adding layers of coordination and complexity.

1. **Logistical Challenges**: Global distribution required a robust cold-chain infrastructure, particularly to maintain the vaccine at –70°C, a significant hurdle for low- and middle-income countries lacking adequate storage facilities. (Lewis, Badkar, Cirelli, Combs, & Lerch, 2022).

* **Quality Control**: The vaccine production operated under a stringent quality requirement with a tolerance of only ±1 sigma, making it highly challenging to maintain such precision within an accelerated development and manufacturing schedule.

(Lewis et al., 2022)

**Project Evaluation & Financial Analysis**

Critical path: The critical path shown in Fig 1 was identified as

**Announcing partnership---------🡪Starting project with 4 variants----------🡪 Phase1,2,3 trials---------🡪Manufacturing and scale-up----------🡪Global rollout and distribution**

A graph with red and blue lines

AI-generated content may be incorrect.A delay in any of these above steps in critical path would have delayed the wholeprocess claiming many lives globally.

**Project Crashing:**

The rapid development of an emergency vaccine serves as an ideal example of project crashing, where time-intensive activities were executed concurrently to accelerate delivery. The steps followed were:

* Strategic Partnership Initiation  
  The collaboration between Pfizer and BioNTech was finalized in under a month—an exceptionally short time for such high-stakes partnerships. This early alignment enabled both companies to rapidly combine R&D capabilities, manufacturing infrastructure, and regulatory strategies to fast-track vaccine development (Pfizer, 2021).
* Parallel Manufacturing and Trials  
  Unlike conventional linear development models, preparations for large-scale manufacturing were launched in parallel with preclinical research and clinical trials, even before selecting a definitive vaccine candidate. This proactive crashing approach ensured production scalability was not delayed post-approval (Lewis et al., 2022).
* Digitally Accelerated Clinical Trials  
  Pfizer deployed AI and predictive modeling to select optimal clinical trial sites across six countries. The trial cohort expanded to 46,000 participants in just four months, supported by remote monitoring tools, with 75% of trial site visits conducted virtually. A centralized Digital Operations Center enabled real-time manufacturing oversight and adaptive decision-making (Pfizer, 2021).
* Cold Chain Logistics Integration  
  Cold chain logistics-crucial for mRNA vaccine efficacy-were built concurrently with late-stage clinical trials. Pfizer utilized IoT sensors and GPS tracking to ensure near-perfect temperature control and delivery accuracy. Planning also included the use of multi-dose vials within trial designs to conserve doses and streamline distribution (Pfizer, 2021; Lewis et al., 2022).
* Remote Maintenance and Equipment Diagnostics  
  Augmented Reality (AR) was integrated to allow remote troubleshooting and equipment maintenance in manufacturing facilities, minimizing delays caused by technical malfunctions or global travel restrictions during the pandemic (Pfizer, 2021).

This integrated crashing strategy allowed Pfizer and BioNTech to develop, test, manufacture, and distribute a globally approved vaccine in just 9 months, compared to the traditional 10–15-year timeline-demonstrating an unprecedented example of accelerated yet high-quality project execution.

**Net present value (NPV) and Expected monetary value(EMV):**

To calculate NPV and EMV, assuming the time now is March 2020, when the deal between Pfizer and BioNtech was signed. As it is a new virus , we need to make few assumptions studing the schorlary article of Plotkinet al., (Plotkin, Robinson, Cunningham, Iqbal, & Larsen, 2017)

1. NPV:

* Initial costs, R&D and manufacturing setup : $1 billion ()
* Future Cash Flows (C): $5 billion per year over 5 years (expected revenue from sales)
* Discount Rate (r): 10% (assumed rate based on pharma industry standards)

NPV=∑ C(1+r)t−initial costs

Which gives NPV = $11.27 billion. A positive NPV indicates a profitable project.

1. EMV

Probability of Success: 0.80 (80% chance of success), Revenue for Success: $5 billion

Probability of Failure: 0.20 (20% chance of failure), Cost of Failure: $1 billion (

EMV Formula:

EMV= ((P(success)×Revenue(success))+(P(failure)×Loss(failure))

EMV = $3.8 billion, a positive EMV indicates a favorable expected value.

Even practically By the end of 2021, Pfizer had successfully produced over 3 billion vaccine doses, with more than 2.6 billion doses delivered to 166 countries and territories, generating $36.7 billion in revenue despite R&D expenses of $13.8 billion (Pfizer, 2021).

A screenshot of a computer

AI-generated content may be incorrect.

**Project Planning & Execution**

Pfizer’s motto of “Pfizer's purpose is breakthroughs that change patients’ lives. We pursue that goal relentlessly and innovate every day to make the world a healthier place.” Perfectly aligns with Project Lightning speed to deliver a innovate solution to pandemic.

The urgency of the pandemic skewed the Pfizer-BioNTech COVID-19 vaccine project towards time with the following scope creep:

* Initially, suppliers of lipid nanoparticles were used to serving academic centers, not mass production for a pandemic, requiring Pfizer to scale and engage new suppliers.
* Manufacturing operations were redesigned to operate in parallel, by passing the usual sequential process to speed up production.
* Just-in-Time Distribution: Pfizer opted for a just-in-time distribution system, bypassing McKesson shipping which the federal government chose, and directly shipping vaccines from plants to vaccination points.
* Pfizer integrated software capabilities to adapt quickly to evolving virus strains, adding complexity to the project scope.

The **Work Breakdown Structure (WBS)** involved key components:

1. **R&d ,Clinical Trials**: Phases 1-3, conducted across multiple countries.
2. **Regulatory Affairs**: Coordination with health authorities for rolling submissions and emergency approvals.
3. **Manufacturing**: Manufacturing processes, including the use of lipid nanoparticles, and increasing production capacity.
4. **Global Logistics**: Cold-chain management and distribution to vaccination centers worldwide.

A diagram of a work breakdown structure

AI-generated content may be incorrect.

* **Cost Performance Index (CPI**) = Earned value/ Actual cost=1.81

[Earned value = revenue in 2021, $36.7 billion; Actual cost= $ 20.25 billion

3 billion doses sold till 2021, the production cost of Pfizer's Comirnaty vaccine has been estimated at around $6.75 per dose (De Haan and Ten Kate (2023)]

As CpI > 1 , this means the project is under budget and performing efficiently., which is a commendable achievement given the scale and time contsraints.

**Quality control**: (Lewis et. al,2021)

* Comparability Evaluations: Pfizer ensured consistent product quality across global manufacturing sites through comprehensive evaluations and computational fluid dynamics for uniform mixing
* Temperature-Controlled Shipping: Developed a thermal shipper to store 5,850 doses and track temperature, location, and light exposure in real-time, also serving as cold storage where freezers were unavailable
* Freezer Farms: Expanded freezer farms at manufacturing plants worldwide to maintain appropriate vaccine storage temperatures
* Raw Material Sourcing: Internal production of lipids (ALC-0159, ALC-0315, DSPC, and cholesterol) and collaboration with chemical companies to secure materials .
* Vial and Cap Supply: Overcame challenges in securing vials and caps by leveraging existing supplier relationships
* Quality Control Testing: Extensive testing for active substances and finished products, including RNA integrity, pH, encapsulation, and sterility.

**Stake holder analysis:**

**A diagram of people with text

AI-generated content may be incorrect.**

Stakeholders analysis showed we need to closely monitor government and public health authorities through constant feedback and coordination.

**Risk analysis and mitigation:**

* Accelerated Timeline Challenges: The race against time meant even small delays could have severe global consequences. To mitigate this, Pfizer and BioNTech executed multiple project phases simultaneously, ensuring rapid progress without waiting for one phase to complete before starting another.
* Navigating Regulation : The complexity of regulatory approvals could slow down progress. This risk was mitigated by adopting a flexible strategy with constant communication and real-time data sharing with regulatory bodies, facilitating quicker approvals .
* Stakeholder Coordination: Collaborating with numerous stakeholders could lead to confusion and miscommunication. To address this, clear communication channels and regular meetings were established, ensuring all parties remained aligned.
* Distribution Issues: Ensuring vaccines were stored and transported at the correct temperatures, especially in regions with inadequate infrastructure, was a significant challenge. To mitigate this, Pfizer and BioNTech invested in advanced cold-chain technology and tracking systems, ensuring vaccine viability during transit. (Pfizer ,2021).
* Maintaining Quality Control: Rapid production raised room for error. To mitigate this, rigorous quality checks and real-time monitoring were implemented throughout the manufacturing process, ensuring every dose met stringent quality standards.

**Project Methodologies & Leadership**

**Success factors:**

* Taking about leadership, both CEOs of Pfizer and BioNTech displayed exceptional leadership and a strong commitment to ensuring the success of the project. BioNTech's CEO, Ugur Sahin, played a pivotal role with his proactive approach, working on the vaccine even before the World Health Organization declared the pandemic.
* Pfizer took an independent approach to logistics, choosing to bypass government recommendations in order to expedite the supply process.
* Although Pfizer and BioNTech officially partnered in March 2020, a formal legal agreement was not finalized until 2022, reflecting their strong commitment and mutual trust throughout the collaboration.
* Tiered cost strategy for high, middle and low income countries.
* The rapid development and distribution of the vaccine ultimately saved millions of lives worldwide.

The collaboration between Pfizer and BioNTech exemplified how adaptive project management, willingness to take risks, and strong leadership can lead to **SUCCESSFUL** outcomes even in times of crisis.

**Discrepancies :**

* Despite the success of the project, some discrepancies were observed, particularly regarding the unequal distribution of costs between high, middle, and low-income countries.
* CEO Ugur Sahin became a billionaire as a result of the project.
* The selling price of the vaccine was higher than the production costs.

**Recommendations:**

* **What Worked**: Parallel workflows, strategic risk-taking (manufacturing at-risk), and proactive stakeholder engagement led to successful vaccine delivery.
* **What Could Be Improved**: A more robust early focus on equitable distribution and earlier investments in cold-chain infrastructure for lower-income countries.
* **Future Project Learnings**: The project suggests institutionalizing hybrid regulatory frameworks, showing how apt and crucial agile project management is in vaccine development, and maintaining global dashboards for real-time resource allocation across global stakeholders help in effective real time coordination.

**\*Take aways from interview with Ms Irina Lamarr , who is a project management specialist:**

**Using the Stacy Matrix to Determine Uncertainty**: The Stacy Matrix helps assess the level of uncertainty in a project by evaluating both the certainty of the solution and the agreement among stakeholders. It categorizes projects into simple, complicated, complex, and chaotic types, each requiring a different management approach.

**Using a Hybrid Agile Methodology for Project Management**: A hybrid Agile approach combines elements of Agile with other traditional methodologies to better handle projects with varying levels of complexity, providing flexibility and adaptability while maintaining structure and predictability.

**Alternative Methods to Agile Project Management**: In addition to Agile, other project management methods like Waterfall, preventive techniques offer different frameworks and techniques that may be more suitable for projects with defined processes, limited uncertainty, or a need for efficiency and quality control

**References;**

1. The Guardian. (2021, March 6). *From Pfizer to Moderna: Who’s making billions from COVID vaccines*. The Guardian. <https://www.theguardian.com/business/2021/mar/06/from-pfizer-to-moderna-whos-making-billions-from-covid-vaccines>

2. Harvard Business Review. (2020, December). *COVID-19 vaccine trials are a case study on the challenges of data literacy*. Harvard Business Review. <https://hbr.org/2020/12/covid-19-vaccine-trials-are-a-case-study-on-the-challenges-of-data-literacy>

3.McKinsey & Company. (n.d.). *How digital helps a life sciences leader move at light speed*. McKinsey & Company. <https://www.mckinsey.com/industries/life-sciences/our-insights/how-digital-helps-a-life-sciences-leader-move-at-light-speed/>

4. Pfizer. (2021). *Latest digital technology to COVID vaccine efforts*. Pfizer. [https://www.pfizer.com/sites/default/files/investors/financial\_reports/annual\_reports/2021/story/latest-digital-technology-to-covid-vaccine-efforts//](https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2021/story/latest-digital-technology-to-covid-vaccine-efforts/)

5. Pfizer. (2021). *Pfizer annual performance 2021*. Pfizer. <https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2021/performance/>

6. U.S. Securities and Exchange Commission. (2021). *Pfizer Inc. annual report 2021*. <https://www.sec.gov/Archives/edgar/data/78003/000007800322000003/pfe-12312021xex99.htm>

7. CNBC. (2021, October 23). *How BioNTech went from a little-known company to creating the COVID vaccine*. CNBC. <https://www.cnbc.com/2021/10/23/how-biontech-went-from-a-little-known-to-creating-covid-vaccine-.html>

8. Immunization Economics. (2024, September 25). *Analysis of the global health and economic value of COVID-19 vaccination*. Immunization Economics. <https://immunizationeconomics.org/recent-activity/2024/9/25/analysis-of-the-global-health-and-economic-value-of-covid-19-vaccination/>

9. Asana. (n.d.). *The project management triangle*. Asana. <https://asana.com/resources/project-management-triangle>

10. Pfizer. (2021). *Manufacturing and distribution of the COVID-19 vaccine*. Pfizer. <https://www.pfizer.com/science/coronavirus/vaccine/manufacturing-and-distribution>

11. The Guardian. (2021, November 2). *Pfizer’s COVID-19 vaccine sales in 2021*. The Guardian. <https://www.theguardian.com/business/2021/nov/02/pfizer-covid-19-vaccine-sales-2021-biontech>

12. De Haan, E., Ten Kate, A., Stichting Onderzoek Multinationale Ondernemingen, & Centre for Research on Multinational Corporations. (2023). *Pharma’s pandemic profits* [Report]. <https://www.somo.nl/wp-content/uploads/2023/02/SOMO-Pharmas-Pandemic-Profits.pdf>

13.CNBC. (2021, October 23). *How BioNTech went from a little-known company to creating the COVID vaccine*. CNBC. <https://www.cnbc.com/2021/10/23/how-biontech-went-from-a-little-known-to-creating-covid-vaccine-.html>

**Scholarly article, journals:**

Leisinger, K., & Schroeder, D. (2024). Project lightspeed: A case study in research ethics and accelerated vaccine development. *Research Ethics*, *20*(4), 847–856. <https://doi.org/10.1177/17470161241251597>

Lewis, L. M., Badkar, A. V., Cirelli, D., Combs, R., & Lerch, T. F. (2022). The race to develop the Pfizer-BioNTech COVID-19 vaccine: From the pharmaceutical scientists’ perspective. *Journal of Pharmaceutical Sciences*, *112*(3), 640–647. <https://doi.org/10.1016/j.xphs.2022.09.014>

*Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Pfizer-BioNTech COVID-19 vaccine*. (2024, August 21). Advisory Committee on Immunization Practices (ACIP). <https://www.cdc.gov/acip/grade/covid-19-pfizer-biontech-vaccine.html>

Meskell P, Biesty LM, Dowling M, Meehan E, Glenton C, Devane D, Shepperd S, Booth A, Cox R, Chan XHS, Houghton C. Factors that impact on recruitment to vaccine trials during a pandemic or epidemic: a qualitative evidence synthesis. Cochrane Database Syst Rev. 2022 Jan 11;2022(1):MR000065. doi: 10.1002/14651858.MR000065. PMCID: PMC8751669.

Chen J, Ali F, Khan I, Zhu YZ. Recent progress in the development of potential drugs against SARS-CoV-2. Curr Res Pharmacol Drug Discov. 2021;2:100057. doi: 10.1016/j.crphar.2021.100057. Epub 2021 Sep 14. PMID: 34870155; PMCID: PMC8437701.

Plotkin S, Robinson JM, Cunningham G, Iqbal R, Larsen S. The complexity and cost of vaccine manufacturing - An overview. Vaccine. 2017 Jul 24;35(33):4064-4071. doi: 10.1016/j.vaccine.2017.06.003. Epub 2017 Jun 21. PMID: 28647170; PMCID: PMC5518734.

Light DW, Lexchin J. The costs of coronavirus vaccines and their pricing. J R Soc Med. 2021 Nov;114(11):502-504. doi: 10.1177/01410768211053006. Epub 2021 Nov 3. PMID: 34732097; PMCID: PMC8649487.